v3.8.0.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2017
Jun. 30, 2017
Current assets:    
Cash $ 5,916 $ 8,088
Accounts receivable - trade 260 175
Work in process 0 26
Prepaid expenses and other current assets 206 283
Total Current Assets 6,382 8,572
Fixed assets, net of accumulated depreciation 25,268 25,589
Intangible assets, net of accumulated amortization 1,757 1,823
Security deposit 26 26
Total Assets 33,433 36,010
Current liabilities:    
Accounts payable (related party of $56 and $87 as of September 30, 2017 and June 30, 2017, respectively) 596 749
Accrued expenses (related party of $778 and $650 as of September 30, 2017 and June 30, 2017, respectively) 1,047 924
Capital lease obligation - current portion 187 183
Deferred revenue 276 157
Total Current Liabilities 2,106 2,013
Capital lease obligation - net of current portion 25,034 25,082
Total Liabilities 27,140 27,095
Commitments and Contingencies
iBio, Inc. Stockholders’ Equity:    
Preferred stock - $0.001 par value; 1,000,000 shares authorized; 1 share issued and outstanding as of both September 30, 2017 and June 30, 2017 0 0
Common stock - $0.001 par value; 175,000,000 shares authorized; 92,818,510 and 89,118,510 shares issued and outstanding as of September 30, 2017 and June 30, 2017, respectively 93 89
Additional paid-in capital 82,178 80,977
Accumulated other comprehensive loss (29) (29)
Accumulated deficit (75,949) (72,123)
Total iBio, Inc. Stockholders’ Equity 6,293 8,914
Noncontrolling interest 0 1
Total Equity 6,293 8,915
Total Liabilities and Equity $ 33,433 $ 36,010

Source

v3.8.0.1
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Revenues $ 122 $ 135
Operating expenses:    
Research and development (related parties of $176 and $239), net of $44 and $36 in grant income 985 820
General and administrative (related parties of $206 and $175) 2,498 2,469
Total operating expenses 3,483 3,289
Operating loss (3,361) (3,154)
Other income (expense):    
Interest expense (related party of $480 and $483) (480) (483)
Interest income 5 13
Royalty income 9 12
Total other income (expense) (466) (458)
Consolidated net loss (3,827) (3,612)
Net loss attributable to noncontrolling interest 1 551
Net loss attributable to iBio, Inc. (3,826) (3,061)
Preferred stock dividends (66) 0
Net loss available to iBio, Inc. (3,892) (3,061)
Comprehensive loss:    
Consolidated net loss (3,827) (3,612)
Other comprehensive loss - foreign currency translation adjustments 0 0
Comprehensive loss $ (3,827) $ (3,612)
Loss per common share attributable to iBio, Inc. stockholders - basic and diluted $ (0.04) $ (0.03)
Weighted-average common shares outstanding - basic and diluted 91,853 89,109

Source

v3.8.0.1
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
3 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Cash flows from operating activities:    
Consolidated net loss $ (3,827) $ (3,612)
Adjustments to reconcile consolidated net loss to net cash used in operating activities:    
Share-based compensation 205 265
Amortization of intangible assets 85 88
Depreciation 338 324
Changes in operating assets and liabilities:    
Accounts receivable - trade (85) 315
Accounts receivable - unbilled 0 61
Work in process 26 22
Prepaid expenses and other current assets 77 131
Security deposit 0 2
Accounts payable (78) 53
Accrued expenses 123 102
Deferred revenue 119 (24)
Net cash used in operating activities (3,017) (2,273)
Cash flows from investing activities:    
Additions to intangible assets (15) (202)
Purchases of fixed assets (96) (400)
Net cash used in investing activities (111) (602)
Cash flows from financing activities:    
Proceeds from sale of common stock 1,000 0
Payment of capital lease obligation (44) (41)
Net cash provided by (used in) financing activities 956 (41)
Net decrease in cash (2,172) (2,916)
Cash - beginning of period 8,088 23,014
Cash - end of period 5,916 20,098
Schedule of non-cash activities:    
Unpaid intangible assets included in accounts payable 7 184
Intangible assets included in accounts payable in FY 2017, paid in FY 2018 11 0
Unpaid fixed assets included in accounts payable 9 71
Fixed assets included in accounts payable in FY 2017, paid in FY 2018 87 0
Supplemental cash flow information:    
Cash paid during the period for interest $ 481 $ 484

Source